Fujifilm Wako Pure Chemical Corp. launches MassivEVTM products for mass purification of extracellular vesicles; products promise high efficiency and purity to support exosome research and potential applications in healthcare, cosmetics, and food R&D

Sample article from our Health Care Sector

OSAKA, Japan , January 22, 2024 (press release) –

FUJIFILM Wako Pure Chemical Corporation (President: Koichi Yoshida) today announced the launch of the MassivEVTM EV Purification Column PS and MassivEVTM Purification Buffer Set, products designed for high-purity and high-efficiency mass purification of extracellular vesicles (EVs) to support exosome research.

EVs are lipid bilayer-delimited vesicles released by cells containing a variety of physiological active substances including lipids, nucleic acids, and proteins involved in intercellular communication that play a role in disease and health1. EVs secreted by mesenchymal stem cells are reported to have a therapeutic effect on various diseases and skin conditions2, prompting active R&D in the areas of healthcare, cosmetics, and food. In the medical field, there is a growing need for mass purification of high-quality EVs for application in diagnostic and drug delivery pharmaceutical manufacturing processes.

The MassivEV EV Purification Column PS and the MassivEV Purification Buffer Set are capable of EV purification from liter-scale cell culture supernatants compatible with safety and pharmacological testing. The products are based on the PS Affinity method3, FUJIFILM Wako Pure Chemical’s proprietary EV isolation technique, developed by Professor Rikinari Hanayama of Kanazawa University. The MassivEV products can achieve efficient single-step purification of EVs in higher purity than those obtained with the conventional mass EV purification method4, which requires multiple purification steps5.

FUJIFILM Wako Pure Chemical is working to achieve compliance with the Standards for Biological Ingredients6 and ISO20399and promoting further process development for future applications in commercial-scale manufacturing.

With commitment to the future of science and dedication to creating happiness, FUJIFILM Wako Pure Chemical will continue to develop and supply high-quality products that cater to the needs of our society and customers, and contributing to the advancement of academic research, industries and healthcare.

The new MassivEV products are currently available in the U.S. market.

1Wang X et al. 2023. Cancer Gene Ther 30(8):1051-1065, PMID: 37106070.
2Kee LT et al. 2022. Int J Mol Sci 23(12):6742, PMID: 35743181.
3Method that uses Affinity purification method that leverages the biological interaction between specific molecules to selectively supplement and separate target molecules. The PS Affinity method targets Tim4 (T-cell immunoglobulin domain and mucin domain-containing protein 4), a protein which specifically binds phosphatidylserine (PS) present on the surface of EVs. Tim4 binds to PS in a calcium ion-dependent manner, allowing for EV capture on Tim4-coated magnetic beads in the presence of calcium ions, followed by elimination of contaminants and subsequent release of high-purity, intact EVs via a chelating reagent. (Yoshida and Hanayama. 2022. Methods Mol Biol 2466:23-36, PMID: 35585308).
4Conventional mass EV purification methods combine filtration-based Tangential Flow Filtration (TFF), Anion-Exchange Chromatography (AEX), and Size Exclusion Chromatography (SEC) steps.
5Per Fujifilm data obtained in November 2023
6Japanese Ministry of Health, Labor and Welfare Ordinance on Good Clinical Practice for Drugs item 37, setting out requirements for pharmaceutical manufacturing (including those used in manufacturing processes as additives, culture medium, etc) using materials derived from human and other lifeforms (excluding plants).
7International specifications defined by the International Standardization Organization (ISO) concerning ancillary materials present during the production of cellular therapeutic products.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.